This Page Is Inserted by IFW Operations and is not a part of the Official Record

BEST AVAILABLE IMAGES


Defective images within this document are accurate representations of the original documents submitted by the applicant.


Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents will not correct images, please do not report the images to the Image Problem Mailbox.





40

Figure 3

ser Tim Home	A Subject GEG 23h11945/SQL Visit First Visit // Page: ## Fage submitted by Tim with Design viole at 15.52/02 fon Tuer Mays 15/2001.
RO Any CRO Name Sporisor Any Pharmaceutical Name Product COPD New Drug Project Primary Indication	
Trial Phase III No. 1 Country England Centre East Anglia No.1 Subject GFG 23111945/54 Visit First Visit	Please Istiany: significant medical history/concomitant diseases (not related to trial indication). History or diagnosis
Page History	(Enterpolic one per feld: 1. Date of diagnosis surgery Active problem? (User precise medical terminology)) (day month year) (Fe (Circle appropriate code) (1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1
ontext RO Any Cro-Name	
ponsor Any Pharmaceutical Name oduct COPD New Drug oject Primary Indication (al Phase III No. 1 pontry England entre East Anglia No. 1 pipect GFG 23111945/54 sit First Visit age History	
Versional of the Previous Cales Delete Cales Pvs Visiters QC (NA) 1005	Submit Level
III EFF UP GO NAS AOK MOKA	Docal time Tue (May 15 \ \$52.37 200 (851)


48

42

cd- dev3- a- 56

Figure 5

Figure 4



History Back Forward	ase:1111 no 111	pnase 111 no 1"	Sponsor 0 CRO: 0 Centre 4 Sponsor 0 Cubject: 8 Project: 0 Cycle 8 Visit: 25 Frai: 0 Visit: 25	g Totals NE - 0 Received Enter Received Enter Cycle; Gycle; Since Totals Received Enter Cycle; Since Totals Received Enter Cycle; Since Totals Received Enter Cycle; Since Totals Received Enter B	0 - 70 COK-0	A Company of the Co
lan Davey (ip:dev3=d/4) Validation	Leyel Context Name # #	Validation Trial (ID-MH-2002 0£ 100 pharma company	product new drug 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	Sublevels——————————————————————————————————	CErri CU cir CNA cAOK CIOX Tiype country usa	